Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1...
Khondrion has joined a recently established consortium of universities and industry partners to train international PhD students whose research is...
Sonlicromanol for MELAS spectrum disorders – a rare, progressive primary mitochondrial disease – to move into a Phase III registrational study...
NIJMEGEN, the Netherlands – 25 October 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 14 September 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing,...
Classic MELAS syndrome (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), MIDD (maternally inherited diabetes mellitus...
1. Tell us all about your career before joining Khondrion I studied pharmacology and molecular biology at the University of Strasbourg in France,...
Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the Mitochondrial Medicine conference held from 11-13 December 2019 at the...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
Reflections on SSIEM annual symposium 2019 – Building Bridges Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the...
